Abstract
Introduction: Naegleria fowleri is a free-living protist pathogen. Given the opportunity, it can produce infection of the central nervous system. It is distressing that the brain-eating amoebae, Naegleria fowleri remains one of the lethal parasites resulting almost always in death, despite advances in antimicrobial chemotherapy and supportive care. Areas covered: The overall aim is to present a timely review of our current understanding of emerging therapies and priorities. By searching bibliographic databases (PubMed) for the available peer-reviewed research literature, herein, we discuss current advances, challenges and opportunities pertinent in the development of therapeutic interventions. Expert opinion: The prospect of exploring repurposed drugs in combination with nanotechnology and a theranostic approach to concurrently achieve diagnosis and drug delivery will offer promise in the rational development of effective therapies to counter N. folweri-associated fatal brain infections.
Original language | English |
---|---|
Pages (from-to) | 41-49 |
Number of pages | 9 |
Journal | Expert Opinion on Orphan Drugs |
Volume | 12 |
Issue number | 1 |
DOIs | |
Publication status | Published - 31 Dec 2024 |
Keywords
- brain-eating amoeba
- CNS infections
- emerging therapies
- free-living amoebae
- Naegleria fowleri
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
- Health Policy
- Pharmacology (medical)